Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez image

Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez

Jun 23, 2022
07:00PM - 08:00PM EDT
Online Event
Overview

Bispecific antibodies have the potential to change myeloma treatment forever. Get to know this exciting immunotherapy. There are many bispecific antibodies being tested in clinical trials and awaiting FDA approval. What are some of their mechanisms of action? What is their potential in treating myeloma? Come with your questions and learn with us.

Agenda
07:00 PM
Introduction
Audrey Burton-Bethkee
Audrey introduces the agenda of the event and featured speaker Dr. Cesar Rodriguez.
07:05 PM
Presentation
Dr. Cesar Rodriguez
Dr. Rodriguez talks about how bispecific antibodies have the potential to change myeloma treatment forever.
07:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them!
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Cesar Rodriguez, MD

Cesar Rodriguez, MD

Dr. Cesar Rodriguez is Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, and the Center of Excellence for Multiple Myeloma, and serves as Clinical Director of Multiple Myeloma at The Mount Sinai Hospital. Dr. Rodriguez has extensive experience treating patients with plasma cell disorders. He is a member of the International Myeloma Working Group which conducts collaborative research and produces consensus guidelines for the myeloma community. Dr. Rodriguez has more than 10 years of experience in clinical research and is the principal investigator of numerous clinical trials for multiple myeloma focused on early drug development and immunotherapies that include T cell and NK cell directed therapies. He is also working on a 3D organoid model to better understand the biology of the tumor niche.